US Patent Issued to Beth Israel Deaconess Medical Center on Aug. 18 for "Anti-IL-1Beta antibody therapy in arrhythmogenic cardiomyopathy (ACM)" (Massachusetts Inventor)

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,708,665, issued on Aug. 18, was assigned to Beth Israel Deaconess Medical Center Inc. (Boston).

"Anti-IL-1Beta antibody therapy in arrhythmogenic cardiomyopathy (ACM)" was invented by Jeffrey E. Saffitz (Waban, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are, inter alia, methods for treating arrhythmogenic cardiomyopathy (ACM) using anti-inflammatory agents that IL-1Beta."

The patent was filed on Sept. 25, 2020, under Application No. 17/763,780.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.ht...